Genmab gains on Phase I/II daratumumab data

Genmab A/S (CSE:GEN) rose DKK49.50 to DKK610 on Thursday after data from a Phase I/II trial of daratumumab (HuMax- CD38) as monotherapy in relapsed or refractory multiple myeloma (MM) patients were Velcade bortezomib and Revlimid lenalidomide.

Patients received either 8 mg/kg or 16 mg/kg doses. Genmab said its partner, the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ), will use the 16 mg/kg dose in future studies of the human mAb against CD38. ...